Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Non-Current Debt (2016 - 2022)

Plus Therapeutics (PSTV) has disclosed Non-Current Debt for 9 consecutive years, with $3.8 million as the latest value for Q4 2022.

  • On a quarterly basis, Non-Current Debt changed N/A to $3.8 million in Q4 2022 year-over-year; TTM through Dec 2022 was $3.8 million, a N/A change, with the full-year FY2022 number at $3.8 million, changed N/A from a year prior.
  • Non-Current Debt was $3.8 million for Q4 2022 at Plus Therapeutics, down from $4.1 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $4.7 million in Q1 2022 to a low of $3.8 million in Q4 2022.